Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Not Allowed)
ID: 347403Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/347403

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-165.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity for the development and application of positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging ligands, aimed at enhancing research in central nervous system (CNS) disorders. This grant, under the R01 Research Project Grant mechanism, invites applications focused on the preclinical development of novel radioligands to support drug discovery and pathophysiological studies, with an emphasis on understanding brain function and evaluating therapeutic candidates. The program is particularly significant for advancing imaging capabilities related to mental health and age-related diseases, and it encourages collaboration between academia and industry while prohibiting clinical trial proposals. Interested applicants must submit their proposals by May 7, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-23-165.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-165-Full-Announcement.html
    PAR-23-165.html
    The Department of Health and Human Services has issued a Notice of Funding Opportunity (NOFO) for the development of PET and SPECT imaging ligands, aimed at enhancing research in central nervous system (CNS) disorders. The funding, managed by the National Institutes of Health (NIH) through the R01 Research Project Grant mechanism, encourages preclinical research to create novel radioligands to aid in drug discovery and pathophysiological studies of mental illnesses and age-related diseases. Key objectives include advancing understanding of brain function, evaluating therapeutic candidate engagement, and the creation of biomarkers for disease progression and treatment efficacy. With application due dates beginning June 5, 2023, proposals must follow specific submission formats and address detailed project goals, including the feasibility of tracer development and engagement with biological experts. The program emphasizes collaboration between academia and industry, with no allowance for clinical trials within the proposals. While budget amounts are flexible, applicants must ensure all requirements are strictly adhered to, supported by detailed research plans and timelines. This funding opportunity is significant for enhancing CNS imaging capabilities and understanding disorders impacting mental health and aging.
    Similar Opportunities
    Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity aimed at the development and application of positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging ligands as biomarkers for drug discovery and studies of central nervous system (CNS) disorders. This initiative invites research grant applications that propose the development and evaluation of novel radioligands for human brain imaging, with an emphasis on their potential to enhance understanding and treatment of mental disorders such as depression and cognitive decline. The program supports both clinical and preclinical projects, encouraging collaborative research between academia and industry, and requires applications to justify the relevance and feasibility of their proposed tracers. Interested applicants should note that the submission deadline is May 7, 2026, and can find more details and guidelines at the NIH Grants Information website or by contacting grantsinfo@nih.gov.
    Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for research aimed at the development and application of novel radioligands for positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging, specifically as biomarkers for drug discovery and studies related to central nervous system (CNS) disorders. This initiative invites applications focused on preclinical development, emphasizing the need for collaborative research between academia and industry to enhance understanding of brain disorders and support drug development processes. The funding opportunity is open to a diverse range of eligible institutions, including those serving underrepresented groups, with a submission deadline of May 7, 2026. Interested applicants can find more information and guidelines at the NIH Grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)" aimed at supporting research into novel small molecules that can modulate biological targets relevant to mental health, aging, drug abuse, and eye diseases. The initiative seeks to stimulate the discovery and development of in vivo chemical probes, requiring applicants to have validated starting compounds for optimization and bioassays to test new analogs. This funding is crucial for advancing the understanding of brain disease mechanisms and emphasizes projects that provide insights into significant biological processes. Interested applicants can submit proposals until January 7, 2027, with no budget limit specified, although actual needs must be indicated. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at NIH Grants.
    Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed)," aimed at advancing research in drug discovery for psychiatric disorders. The initiative focuses on the development and validation of screening assays to identify effective chemical hits for conditions such as depression, bipolar disorder, and schizophrenia, encouraging innovative approaches in mental health research. This grant opportunity is open to a wide range of eligible applicants, including higher education institutions and community-based organizations, with no budget limits and a maximum project period of five years. Interested parties can find more information and submit inquiries via the NIH Grants Information email at grantsinfo@nih.gov, with applications accepted until May 7, 2026.
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for research on neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) and related dementias (ADRD) through the R01 grant mechanism. This initiative aims to encourage studies that enhance understanding of the biobehavioral and neurobiological mechanisms associated with NPS, with the goal of identifying novel therapeutic targets for treatment and prevention. The research is critical for improving care and management strategies for patients and caregivers affected by these conditions, aligning with national efforts to combat Alzheimer's disease. Applications are accepted from a diverse range of eligible institutions, with key submission dates from January 5, 2025, to June 5, 2026. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-065.html.
    Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Not Allowed) to support innovative and exploratory research projects in neuroscience. This grant program is designed for early-stage projects that align with the missions of the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute of Mental Health (NIMH), focusing on studies that assess the feasibility of novel investigations with the potential for significant breakthroughs in neuroscience. Eligible applicants include a wide range of organizations such as educational institutions, nonprofits, and foreign entities, with funding available up to $275,000 over two years. The application period opens on January 16, 2025, with anticipated awards by July 2025; interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)." This initiative aims to support the characterization and efficacy studies of neurotherapeutic agents intended for treating neurological disorders, with a focus on conducting pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate the biological activity of proposed therapeutic agents. The program emphasizes the importance of rigorous experimental design, collaboration, and the inclusion of diverse perspectives in research teams, aligning with NIH's mission to translate research discoveries into effective therapies. Interested applicants can apply for funding up to $499,000 per year for a total project duration not exceeding three years, with the application deadline set for October 20, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-225.html.
    Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)." This initiative aims to develop innovative neurophysiological and behavioral assays in animal models to enhance the therapeutic development pipeline for mental illnesses, focusing on optimizing measures that reflect clinically relevant brain processes. The program encourages research proposals that assess the sensitivity and specificity of these assays as screening tools and promote collaboration between preclinical and clinical studies to facilitate translation to human applications. Interested applicants can apply for grants up to $250,000, with the application deadline set for September 7, 2025. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-091.html.
    Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Exploratory Clinical Neuroscience Research on Substance Use Disorders" (R61/R33), aimed at supporting innovative clinical research that explores the neurobiological mechanisms underlying substance use disorders (SUD). This initiative encourages applications that investigate neural circuitry and cognitive processes affecting substance use behavior, particularly in the context of the ongoing public health crisis related to SUDs, including the opioid epidemic. The R61/R33 mechanism allows for up to five years of funding, divided into an initial two-year R61 phase and a potential three-year R33 phase, contingent upon meeting specified milestones. Interested applicants can find more information and submit proposals by the application due date of March 13, 2026, and may contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for Research Project Grants (R01) aimed at the development of screening assays for drug candidates targeting psychiatric disorders. The primary objectives of this initiative are to stimulate research in the discovery and development of novel small molecules that can potentially treat mental illnesses, as well as to validate compounds that demonstrate desired biological activity through rigorous screening processes. This funding is crucial for advancing therapeutic options for conditions such as depression, schizophrenia, and PTSD, and it encourages applicants to align their proposals with the National Institute of Mental Health (NIMH) priorities. Interested applicants must submit their proposals by May 7, 2026, and can find additional information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.